Utilization of a CMV T Cell Immunity Panel in Directing Duration of Valganciclovir Prophylaxis in CMV High Risk Kidney Transplant Recipients

被引：0
|
作者：
Ray, A. [1 ]
Garner, B. [1 ]
Klein, C. [1 ]
机构：
[1] Piedmont Transplant Inst, Atlanta, GA USA
来源：
AMERICAN JOURNAL OF TRANSPLANTATION | 2023年 / 23卷 / 06期
关键词：
D O I：
暂无
中图分类号：
R61 [外科手术学];
学科分类号：
摘要：
B84
引用
收藏
页码：S793 / S793
页数：1
相关论文
共 50 条
  • [1] Valganciclovir is effective prophylaxis for CMV in high risk renal transplant recipients.
    Baillie, GM
    Ashcraft, EE
    Taber, DJ
    Stone, SS
    Emovon, O
    Rogers, J
    Afzal, F
    Lin, A
    Rajagopalan, PR
    Baliga, PK
    Chavin, KD
    JOURNAL OF THE AMERICAN SOCIETY OF NEPHROLOGY, 2002, 13 : 377A - 377A
  • [2] Risk Factors for Leukopenia with Valganciclovir Prophylaxis in CMV High Risk Cardiothoracic Transplant Recipients
    Brueckner, A. J.
    Doligalski, C. T.
    Logan, A. T.
    JOURNAL OF HEART AND LUNG TRANSPLANTATION, 2017, 36 (04): : S365 - S366
  • [3] Valganciclovir for CMV prophylaxis in paediatric transplant recipients.
    Wiesmayr, S
    Stelzmueller, I
    Jungraithmayr, T
    Mark, W
    Larcher, C
    Margreiter, R
    Zimmerhackl, L
    Bonatti, H
    AMERICAN JOURNAL OF TRANSPLANTATION, 2005, 5 : 355 - 355
  • [4] Valganciclovir as CMV prophylaxis in pediatric transplant recipients.
    Bonatti, H
    Wiesmayr, S
    Junngraithmayr, TC
    Margreiter, R
    Zimmerhackl, LB
    PEDIATRIC TRANSPLANTATION, 2005, 9 : 98 - 98
  • [5] CMV prophylaxis with valganciclovir in CMV-seropositive kidney- and liver-transplant recipients:: A pilot study
    Weclawiack, Hugo
    Kamar, Nassim
    Mengelle, Catherine
    Guitard, Joelle
    Ribes, David
    Lavayssiere, Laurence
    Esposito, Laure
    Cointault, Olivier
    Durand, Dominique
    Rostaing, Lionel
    TRANSPLANT INTERNATIONAL, 2007, 20 : 206 - 206
  • [6] Comparison of Outcomes in Heart Transplant Recipients Receiving CMV Prophylaxis with CMV IVIG with Valganciclovir versus Valganciclovir Alone
    Moss, I.
    Brueckner, A.
    Rumore, A.
    JOURNAL OF HEART AND LUNG TRANSPLANTATION, 2020, 39 (04): : S480 - S480
  • [7] Comparison of Outcomes in Heart Transplant Recipients Receiving CMV Prophylaxis with CMV IVIG with Valganciclovir versus Valganciclovir Alone
    Moss, I.
    Rumore, A.
    Brueckner, A.
    JOURNAL OF HEART AND LUNG TRANSPLANTATION, 2021, 40 (04): : S115 - S116
  • [8] Rates of CMV Infection in Kidney Transplant Recipients Who Received Subtherapeutic Valganciclovir Prophylaxis
    Belfield, K.
    Cohen, E.
    Malinis, M.
    Baghban, A.
    AMERICAN JOURNAL OF TRANSPLANTATION, 2017, 17 : 514 - 514
  • [9] Valganciclovir approved for the prevention of CMV in high-risk kidney, kidney-pancreas transplant recipients
    不详
    DIALYSIS & TRANSPLANTATION, 2003, 32 (11) : 646 - 646
  • [10] Incidence of CMV Disease in High-Risk Liver Transplant Recipients on Low Dose Valganciclovir Prophylaxis
    Tischer, S.
    Park, J.
    Stuckey, L.
    Kaul, D.
    Sonnenday, C.
    Fontana, R.
    AMERICAN JOURNAL OF TRANSPLANTATION, 2013, 13 : 221 - 222
12345